Assessment of visual performance of a new trifocal intraocular lens for visual quality and safety (Optiflex TRIO, Biotech Europe Meditech Inc. Ltd.)

BIOTECH EUROPE MEDITECH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Patient with bilateral age related senile cataract
•2. grade of cataract permitting optical biometry
•3. no ocular/systemic contraindication for surgery
•4. a patient with preoperative corneal astigmatism less than 1D in each eye
•5. normal macular functions with normal anantomy of macula as seen on optical coherence tomography
•6. no history or evidence of ocular anatomical or functional disorders other than cataract including strabismus neuro-ophthalmological disorders of optic nerve or high visual functions corneal pathologies disorders of uvea vitreous pathologies retinal disorders
•7. no systemic contraindications to surgery under local anaesthesia
•8. patient willing to undergo the investigations and comply with the follow-up schedule

•1. cataract precluding optical biometry
•2. posterier-segment pathology
•3. media opacity other than cataract
•4. corneal higher order aberrations more than 0.3 micron as measured on ray-tracing wavefront aberrometer
•5. patients with potential for intraoperative complications such as floppy iris syndrome and pseudo-exfoliation syndrome
•6. cases where intra-operative complications compromise IOL placement with proper centration in the capsule bag
•7. patient unwilling to undergo the required investigations or follow-up

发起方

BIOTECH EUROPE MEDITECH